Subsequently, an activity-escalation trial was initiated, involving 18 patients (16 females with recurrent HER-2 positive ovarian cancer and two males with HER2-positive colon cancer), who were administered escalating activities of 7.4 to 27.4 MBq/m2 with a 30% increase for each subsequent activity level 135. This evidence concerns the gene ERBB2 and ovarian carcinoma.